2022-2023 Key Trends and Updates: Securities Litigation Against Life Sciences Companies

On June 8, 2023, Goodwin’s Caroline Bullerjahn, Courtney Orazio, John Barker, and outside guest speaker, Frank Schneider from Cornerstone Research discussed key updates and recent trends concerning securities class actions filed against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies (collectively, “life sciences companies”), which continue to be a primary target of the plaintiffs’ bar. In 2022, life sciences companies faced by far the most securities class action lawsuits compared to other sectors, even as the overall number of securities class actions filed in 2022 declined for the second straight year (falling 5% from 218 filings in 2021 to 208 filings in 2022).

In addition to analyzing these overall trends, the webinar examined data for class action filings in 2022 and trends based upon such data, focusing on filings against life sciences companies, and reviewed several significant, impactful recent decisions issued by federal courts within life sciences epicenters. It provided in-depth analysis of the potential implications of these decisions, which involve challenges that life sciences companies often face, and discussed practical steps you can take to make informed choices related to your business, including your public disclosures.

*Please note that the webinar and event recordings are for informational purposes only; CLE credit is only available for guests who attended the live webinar.